Financial Ratios Summit Therapeutics Inc.
Equities
SMMT
US86627T1088
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.28 USD | +2.10% |
|
+5.00% | -12.41% |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -32.92 | -49.91 | -10.43 | -12.79 | -41.31 | |||||
Return on Total Capital | -40.97 | -64.91 | -11.09 | -13.38 | -45.49 | |||||
Return On Equity % | -66.57 | -108.89 | -75.05 | -601.85 | -94.9 | |||||
Return on Common Equity | -66.57 | -108.89 | -75.05 | -601.85 | -94.9 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 100 | 100 | 100 | - | - | |||||
SG&A Margin | 2.24K | 1.31K | 3.79K | - | - | |||||
EBITDA Margin % | -5.9K | -4.69K | -9.02K | - | - | |||||
EBITA Margin % | -5.94K | -4.71K | -9.07K | - | - | |||||
EBIT Margin % | -6.09K | -4.76K | -9.2K | - | - | |||||
Income From Continuing Operations Margin % | -6.13K | -4.9K | -11.17K | - | - | |||||
Net Income Margin % | -6.13K | -4.9K | -11.17K | - | - | |||||
Net Avail. For Common Margin % | -6.13K | -4.9K | -11.17K | - | - | |||||
Normalized Net Income Margin | -3.78K | -3.06K | -6.35K | - | - | |||||
Levered Free Cash Flow Margin | -3.35K | -2.12K | -45.29K | - | - | |||||
Unlevered Free Cash Flow Margin | -3.33K | -2.11K | -44.9K | - | - | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.01 | 0.02 | 0 | - | - | |||||
Fixed Assets Turnover | 0.61 | 0.76 | 0.16 | - | - | |||||
Receivables Turnover (Average Receivables) | 1.97 | 1.53 | 0.78 | - | - | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 4.41 | 3.8 | 16.93 | 9.3 | 10.15 | |||||
Quick Ratio | 3.85 | 3.49 | 9.15 | 9.17 | 9.89 | |||||
Operating Cash Flow to Current Liabilities | -2.42 | -2.83 | -1.07 | -3.76 | -3.41 | |||||
Days Sales Outstanding (Average Receivables) | 185.55 | 239 | 469.32 | - | - | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 0.59 | 3.34 | 409.59 | 136.56 | 1.86 | |||||
Total Debt / Total Capital | 0.58 | 3.23 | 80.38 | 57.73 | 1.82 | |||||
LT Debt/Equity | 0.09 | 2.03 | 392.65 | 132.95 | 0.89 | |||||
Long-Term Debt / Total Capital | 0.09 | 1.96 | 77.05 | 56.2 | 0.87 | |||||
Total Liabilities / Total Assets | 22.48 | 26.54 | 80.93 | 61.72 | 10.75 | |||||
EBIT / Interest Expense | -205.23 | -306.71 | -14.74 | -5.39 | -24.29 | |||||
EBITDA / Interest Expense | -197.27 | -297.55 | -14.1 | -5.24 | -23.88 | |||||
(EBITDA - Capex) / Interest Expense | -198.92 | -298.64 | -14.25 | -5.25 | -23.89 | |||||
Total Debt / EBITDA | -0.01 | -0.03 | -8.36 | -1.23 | -0.03 | |||||
Net Debt / EBITDA | 1.31 | 0.83 | -2.74 | 0.93 | 1.95 | |||||
Total Debt / (EBITDA - Capex) | -0.01 | -0.03 | -8.27 | -1.23 | -0.03 | |||||
Net Debt / (EBITDA - Capex) | 1.3 | 0.82 | -2.71 | 0.93 | 1.95 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 6.1 | 110.35 | -61.03 | - | - | |||||
Gross Profit, 1 Yr. Growth % | 6.1 | 110.35 | -61.03 | - | - | |||||
EBITDA, 1 Yr. Growth % | 77.79 | 67.07 | -25.01 | 39.16 | 138.21 | |||||
EBITA, 1 Yr. Growth % | 76.69 | 66.72 | -24.89 | 38.71 | 137.78 | |||||
EBIT, 1 Yr. Growth % | 74.62 | 64.68 | -24.71 | 36.76 | 137.78 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 65.84 | 68.13 | -11.08 | 680.54 | -64.01 | |||||
Net Income, 1 Yr. Growth % | 65.84 | 68.13 | -11.08 | 680.54 | -64.01 | |||||
Normalized Net Income, 1 Yr. Growth % | 64.01 | 70.22 | -19.21 | 31.34 | 119.45 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -21.72 | 26.39 | -57.32 | 142.05 | -68.76 | |||||
Accounts Receivable, 1 Yr. Growth % | -38.82 | 515.71 | -76.16 | - | - | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -16.89 | 172.4 | 45.84 | 19.33 | 22.02 | |||||
Total Assets, 1 Yr. Growth % | 6.49 | 10.61 | 485.82 | -69.44 | 114.62 | |||||
Tangible Book Value, 1 Yr. Growth % | 3.33 | 7.54 | 76.16 | -39.29 | 410.41 | |||||
Common Equity, 1 Yr. Growth % | 0.75 | 4.82 | 52.07 | -38.66 | 400.37 | |||||
Cash From Operations, 1 Yr. Growth % | 112.47 | 50.87 | -42.71 | 84.6 | 85.13 | |||||
Capital Expenditures, 1 Yr. Growth % | 88.25 | -27.32 | 103.92 | -79.49 | 8.59 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | - | 33.12 | 733.65 | -31.15 | -59.88 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | - | 33.25 | 729.75 | -33.8 | -60.5 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | - | 49.39 | -9.46 | - | - | |||||
Gross Profit, 2 Yr. CAGR % | - | 49.39 | -9.46 | - | - | |||||
EBITDA, 2 Yr. CAGR % | - | 72.35 | 11.93 | 2.16 | 83.91 | |||||
EBITA, 2 Yr. CAGR % | - | 71.63 | 11.91 | 2.07 | 83.43 | |||||
EBIT, 2 Yr. CAGR % | - | 69.58 | 11.35 | 1.47 | 82.11 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | - | 66.99 | 22.27 | 163.45 | 67.61 | |||||
Net Income, 2 Yr. CAGR % | - | 66.99 | 22.27 | 163.45 | 67.61 | |||||
Normalized Net Income, 2 Yr. CAGR % | - | 67.09 | 17.27 | 3.01 | 71.29 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | - | -0.53 | -26.55 | 1.64 | -13.05 | |||||
Accounts Receivable, 2 Yr. CAGR % | - | 94.09 | 2.68 | - | - | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | - | 50.46 | 99.31 | 31.92 | 20.67 | |||||
Total Assets, 2 Yr. CAGR % | - | 8.53 | 154.55 | 33.79 | -19.02 | |||||
Tangible Book Value, 2 Yr. CAGR % | - | 5.41 | 37.64 | 3.41 | 76.03 | |||||
Common Equity, 2 Yr. CAGR % | - | 2.76 | 26.26 | -3.42 | 75.2 | |||||
Cash From Operations, 2 Yr. CAGR % | - | 79.04 | -7.03 | 2.83 | 84.86 | |||||
Capital Expenditures, 2 Yr. CAGR % | - | 16.97 | 21.74 | -35.32 | -52.8 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | 233.02 | 139.58 | -47.26 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | 232.51 | 134.37 | -48.67 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | - | - | -4.54 | - | - | |||||
Gross Profit, 3 Yr. CAGR % | - | - | -4.54 | - | - | |||||
EBITDA, 3 Yr. CAGR % | - | - | 30.6 | 20.36 | 35.47 | |||||
EBITA, 3 Yr. CAGR % | - | - | 30.31 | 20.21 | 35.31 | |||||
EBIT, 3 Yr. CAGR % | - | - | 29.37 | 19.24 | 34.77 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | 35.35 | 126.82 | 35.68 | |||||
Net Income, 3 Yr. CAGR % | - | - | 35.35 | 126.82 | 35.68 | |||||
Normalized Net Income, 3 Yr. CAGR % | - | - | 31.14 | 21.78 | 32.54 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | -24.98 | 9.3 | -31.41 | |||||
Accounts Receivable, 3 Yr. CAGR % | - | - | -13.59 | - | - | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | 48.9 | 67.99 | 28.53 | |||||
Total Assets, 3 Yr. CAGR % | - | - | 90.38 | 25.57 | 56.62 | |||||
Tangible Book Value, 3 Yr. CAGR % | - | - | 25.09 | 4.77 | 76.07 | |||||
Common Equity, 3 Yr. CAGR % | - | - | 17.11 | -0.74 | 67.12 | |||||
Cash From Operations, 3 Yr. CAGR % | - | - | 22.46 | 16.85 | 25.1 | |||||
Capital Expenditures, 3 Yr. CAGR % | - | - | 40.78 | -32.76 | -23.13 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 96.92 | 32.43 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 94.16 | 29.85 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | - | - | |||||
Gross Profit, 5 Yr. CAGR % | - | - | - | - | - | |||||
EBITDA, 5 Yr. CAGR % | - | - | - | - | 49.16 | |||||
EBITA, 5 Yr. CAGR % | - | - | - | - | 48.81 | |||||
EBIT, 5 Yr. CAGR % | - | - | - | - | 47.75 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | - | 47.43 | |||||
Net Income, 5 Yr. CAGR % | - | - | - | - | 47.43 | |||||
Normalized Net Income, 5 Yr. CAGR % | - | - | - | - | 45.41 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | - | -20.41 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | - | 36.89 | |||||
Total Assets, 5 Yr. CAGR % | - | - | - | - | 35.25 | |||||
Tangible Book Value, 5 Yr. CAGR % | - | - | - | - | 43.41 | |||||
Common Equity, 5 Yr. CAGR % | - | - | - | - | 37.58 | |||||
Cash From Operations, 5 Yr. CAGR % | - | - | - | - | 44.39 | |||||
Capital Expenditures, 5 Yr. CAGR % | - | - | - | - | -9.07 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | - | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | - |
- Stock Market
- Equities
- SMMT Stock
- Financials Summit Therapeutics Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















